Determination of ED90 and ED99 of oliceridine combined with propofol in Inhibiting responses to gastroscope insertion: A biased coin up-and-down design

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2600118736

Enrollment

Unknown

Registered

2026-02-10

Start date

2024-10-09

Completion date

Unknown

Last updated

2026-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None

Interventions

Experimental group:Remimazolam besylate injection is used at 90% of the minimum effective dose (ED90) for painless gastroscopy, taking G=0.1 (i.e., a 10% probability of anesthesia failure), and b=G/(1

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Age between 18-65, no gender restriction; 2. Classified as ASA I–II by the American Society of Anesthesiologists.

Exclusion criteria

Exclusion criteria: 1. Allergy to the drugs used in this study; 2. Severe liver or kidney damage; 3. Acute gastrointestinal bleeding; 4. Severe mental disorders; 5. Acute upper respiratory tract infection; 6. Poorly controlled hypertension, systolic =160mmHg, diastolic >=100mmHg.

Design outcomes

Primary

Measure	Time frame
inhibiting responses to gastroscope insertion;	—

Secondary

Measure	Time frame
General information (age, gender, body mass index (BMI), ASA classification);Vital signs (HR, MAP, and SpO2);Adverse reactions (monitoring the patient for the occurrence of arrhythmia, tongue falling back, apnea during anesthesia, as well as postoperative nausea and vomiting, abdominal discomfort, and drowsiness);	—

Countries

China

Contacts

Public ContactTang Zhiyong

The First Affiliated Hospital of Dali University

1041312893@qq.com+86 872 220 1120

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 19, 2026